The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma

Basal Cell Carcinoma (BCC) is the most common type of malignant cancer found in the world today with a 3–10% increase in incidence each year. The American Cancer Society reported that 8 out of 10 patients with skin cancer are suffering from BCC with over 2 million new cases each year. BCC needs to b...

Full description

Saved in:
Bibliographic Details
Main Authors: Anthony Paulo Sunjaya, Angela Felicia Sunjaya, Sukmawati Tansil Tan
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Journal of Skin Cancer
Online Access:http://dx.doi.org/10.1155/2017/2692604
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850174478221312000
author Anthony Paulo Sunjaya
Angela Felicia Sunjaya
Sukmawati Tansil Tan
author_facet Anthony Paulo Sunjaya
Angela Felicia Sunjaya
Sukmawati Tansil Tan
author_sort Anthony Paulo Sunjaya
collection DOAJ
description Basal Cell Carcinoma (BCC) is the most common type of malignant cancer found in the world today with a 3–10% increase in incidence each year. The American Cancer Society reported that 8 out of 10 patients with skin cancer are suffering from BCC with over 2 million new cases each year. BCC needs to be detected at the early stages to prevent local destruction causing disabilities to patients and increasing treatment costs. Furthermore, BCC patients who have undergone surgery are still at risk for recurrence, especially when the surgery performed fails to remove all the BCC cells, even when conventional histopathological testing after surgery has reported a surgically free margin. This review aims to evaluate studies on the use of BerEP4 immunohistochemistry staining on pathological sections of various types of BCC as well as its shortfalls. BerEP4 is a monoclonal antibody which detects specific epithelial-glycoprotein-adhesion-molecules (EpCAM) found on BCC cells. Various studies have shown that BerEP4 has a high sensitivity and specificity in detecting only BCC cells. The use of BerEP4 immunohistochemistry testing for the routine examination of cases of BCC is expected to be able to increase and improve early diagnosis as well as prevent recurrence after surgery.
format Article
id doaj-art-d568ad3570ef4e169fde9b85598888ab
institution OA Journals
issn 2090-2905
2090-2913
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Journal of Skin Cancer
spelling doaj-art-d568ad3570ef4e169fde9b85598888ab2025-08-20T02:19:38ZengWileyJournal of Skin Cancer2090-29052090-29132017-01-01201710.1155/2017/26926042692604The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell CarcinomaAnthony Paulo Sunjaya0Angela Felicia Sunjaya1Sukmawati Tansil Tan2Faculty of Medicine, Tarumanagara University, Jl. Letjen S. Parman No. 1, Jakarta 11440, IndonesiaFaculty of Medicine, Tarumanagara University, Jl. Letjen S. Parman No. 1, Jakarta 11440, IndonesiaFaculty of Medicine, Tarumanagara University, Jl. Letjen S. Parman No. 1, Jakarta 11440, IndonesiaBasal Cell Carcinoma (BCC) is the most common type of malignant cancer found in the world today with a 3–10% increase in incidence each year. The American Cancer Society reported that 8 out of 10 patients with skin cancer are suffering from BCC with over 2 million new cases each year. BCC needs to be detected at the early stages to prevent local destruction causing disabilities to patients and increasing treatment costs. Furthermore, BCC patients who have undergone surgery are still at risk for recurrence, especially when the surgery performed fails to remove all the BCC cells, even when conventional histopathological testing after surgery has reported a surgically free margin. This review aims to evaluate studies on the use of BerEP4 immunohistochemistry staining on pathological sections of various types of BCC as well as its shortfalls. BerEP4 is a monoclonal antibody which detects specific epithelial-glycoprotein-adhesion-molecules (EpCAM) found on BCC cells. Various studies have shown that BerEP4 has a high sensitivity and specificity in detecting only BCC cells. The use of BerEP4 immunohistochemistry testing for the routine examination of cases of BCC is expected to be able to increase and improve early diagnosis as well as prevent recurrence after surgery.http://dx.doi.org/10.1155/2017/2692604
spellingShingle Anthony Paulo Sunjaya
Angela Felicia Sunjaya
Sukmawati Tansil Tan
The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma
Journal of Skin Cancer
title The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma
title_full The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma
title_fullStr The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma
title_full_unstemmed The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma
title_short The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma
title_sort use of berep4 immunohistochemistry staining for detection of basal cell carcinoma
url http://dx.doi.org/10.1155/2017/2692604
work_keys_str_mv AT anthonypaulosunjaya theuseofberep4immunohistochemistrystainingfordetectionofbasalcellcarcinoma
AT angelafeliciasunjaya theuseofberep4immunohistochemistrystainingfordetectionofbasalcellcarcinoma
AT sukmawatitansiltan theuseofberep4immunohistochemistrystainingfordetectionofbasalcellcarcinoma
AT anthonypaulosunjaya useofberep4immunohistochemistrystainingfordetectionofbasalcellcarcinoma
AT angelafeliciasunjaya useofberep4immunohistochemistrystainingfordetectionofbasalcellcarcinoma
AT sukmawatitansiltan useofberep4immunohistochemistrystainingfordetectionofbasalcellcarcinoma